These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 34254643)

  • 1. Characterization of systemic immunosuppression by IDH mutant glioma small extracellular vesicles.
    Ludwig N; Rao A; Sandlesh P; Yerneni SS; Swain AD; Bullock KM; Hansen KM; Zhang X; Jaman E; Allen J; Krueger K; Hong CS; Banks WA; Whiteside TL; Amankulor NM
    Neuro Oncol; 2022 Feb; 24(2):197-209. PubMed ID: 34254643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dysfunctional dendritic cells limit antigen-specific T cell response in glioma.
    Friedrich M; Hahn M; Michel J; Sankowski R; Kilian M; Kehl N; Günter M; Bunse T; Pusch S; von Deimling A; Wick W; Autenrieth SE; Prinz M; Platten M; Bunse L
    Neuro Oncol; 2023 Feb; 25(2):263-276. PubMed ID: 35609569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
    Zhang X; Rao A; Sette P; Deibert C; Pomerantz A; Kim WJ; Kohanbash G; Chang Y; Park Y; Engh J; Choi J; Chan T; Okada H; Lotze M; Grandi P; Amankulor N
    Neuro Oncol; 2016 Oct; 18(10):1402-12. PubMed ID: 27116977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Local and systemic effects of IDH mutations on primary glioma patients.
    Tang F; Wang DW; Xi C; Yang JZ; Liu ZY; Yu DH; Wang ZF; Li ZQ
    Immunology; 2023 Aug; 169(4):503-514. PubMed ID: 37054988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The presence of TIM-3 positive cells in WHO grade III and IV astrocytic gliomas correlates with isocitrate dehydrogenase mutation status.
    Sørensen MD; Nielsen O; Reifenberger G; Kristensen BW
    Brain Pathol; 2021 May; 31(3):e12921. PubMed ID: 33244787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of purinergic signaling in tumor-infiltrating lymphocytes from lower- and high-grade gliomas.
    Scholl JN; Weber AF; Dias CK; Lima VP; Grun LK; Zambonin D; Anzolin E; Dos Santos Dias WW; Kus WP; Barbé-Tuana F; Battastini AMO; Worm PV; Figueiró F
    Purinergic Signal; 2024 Feb; 20(1):47-64. PubMed ID: 36964277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas.
    Kohanbash G; Carrera DA; Shrivastav S; Ahn BJ; Jahan N; Mazor T; Chheda ZS; Downey KM; Watchmaker PB; Beppler C; Warta R; Amankulor NA; Herold-Mende C; Costello JF; Okada H
    J Clin Invest; 2017 Apr; 127(4):1425-1437. PubMed ID: 28319047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.
    Turcan S; Fabius AW; Borodovsky A; Pedraza A; Brennan C; Huse J; Viale A; Riggins GJ; Chan TA
    Oncotarget; 2013 Oct; 4(10):1729-36. PubMed ID: 24077826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of IDH mutations on immunotherapeutic strategies for malignant glioma.
    Richardson LG; Miller JJ; Kitagawa Y; Wakimoto H; Choi BD; Curry WT
    Neurosurg Focus; 2022 Feb; 52(2):E6. PubMed ID: 35104795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isocitrate dehydrogenase 1-mutated human gliomas depend on lactate and glutamate to alleviate metabolic stress.
    Lenting K; Khurshed M; Peeters TH; van den Heuvel CNAM; van Lith SAM; de Bitter T; Hendriks W; Span PN; Molenaar RJ; Botman D; Verrijp K; Heerschap A; Ter Laan M; Kusters B; van Ewijk A; Huynen MA; van Noorden CJF; Leenders WPJ
    FASEB J; 2019 Jan; 33(1):557-571. PubMed ID: 30001166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors.
    Malzkorn B; Reifenberger G
    Pathologe; 2019 Jun; 40(Suppl 1):9-17. PubMed ID: 31025086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma.
    Yan D; Li W; Liu Q; Yang K
    Front Immunol; 2022; 13():914618. PubMed ID: 35769466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IDH-mutant gliomas harbor fewer regulatory T cells in humans and mice.
    Richardson LG; Nieman LT; Stemmer-Rachamimov AO; Zheng XS; Stafford K; Nagashima H; Miller JJ; Kiyokawa J; Ting DT; Wakimoto H; Cahill DP; Choi BD; Curry WT
    Oncoimmunology; 2020 Aug; 9(1):1806662. PubMed ID: 32923170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of Distributed Parameter Model to Assessment of Glioma IDH Mutation Status by Dynamic Contrast-Enhanced Magnetic Resonance Imaging.
    Li Z; Zhao W; He B; Koh TS; Li Y; Zeng Y; Zhang Z; Zhang J; Hou Z
    Contrast Media Mol Imaging; 2020; 2020():8843084. PubMed ID: 33299387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune cell gene expression signatures in diffuse glioma are associated with IDH mutation status, patient outcome and malignant cell state, and highlight the importance of specific cell subsets in glioma biology.
    Mehani B; Asanigari S; Chung HJ; Dazelle K; Singh A; Hannenhalli S; Aldape K
    Acta Neuropathol Commun; 2022 Feb; 10(1):19. PubMed ID: 35144680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
    Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential of IDH mutations as immunotherapeutic targets in gliomas: a review and meta-analysis.
    Gonzalez N; Asad AS; Gómez Escalante J; Peña Agudelo JA; Nicola Candia AJ; García Fallit M; Seilicovich A; Candolfi M
    Expert Opin Ther Targets; 2021 Dec; 25(12):1045-1060. PubMed ID: 34904924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase-mutant Glioma.
    Spino M; Kurz SC; Chiriboga L; Serrano J; Zeck B; Sen N; Patel S; Shen G; Vasudevaraja V; Tsirigos A; Suryadevara CM; Frenster JD; Tateishi K; Wakimoto H; Jain R; Riina HA; Nicolaides TP; Sulman EP; Cahill DP; Golfinos JG; Isse K; Saunders LR; Zagzag D; Placantonakis DG; Snuderl M; Chi AS
    Clin Cancer Res; 2019 Feb; 25(4):1261-1271. PubMed ID: 30397180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma.
    Christensen BC; Smith AA; Zheng S; Koestler DC; Houseman EA; Marsit CJ; Wiemels JL; Nelson HH; Karagas MR; Wrensch MR; Kelsey KT; Wiencke JK
    J Natl Cancer Inst; 2011 Jan; 103(2):143-53. PubMed ID: 21163902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. D-2-Hydroxyglutarate Is an Intercellular Mediator in IDH-Mutant Gliomas Inhibiting Complement and T Cells.
    Zhang L; Sorensen MD; Kristensen BW; Reifenberger G; McIntyre TM; Lin F
    Clin Cancer Res; 2018 Nov; 24(21):5381-5391. PubMed ID: 30006485
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.